Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $29.5 Million - $36.7 Million
-125,595 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $421 Million - $496 Million
-1,901,637 Reduced 93.8%
125,595 $32.8 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $340 Million - $430 Million
-1,922,320 Reduced 48.67%
2,027,232 $445 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $109 Million - $122 Million
-599,451 Reduced 13.18%
3,949,552 $716 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $280 Million - $330 Million
-1,493,566 Reduced 24.72%
4,549,003 $917 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $133 Million - $155 Million
-642,853 Reduced 9.62%
6,042,569 $1.3 Billion
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $248 Million - $331 Million
1,199,338 Added 21.86%
6,685,422 $1.58 Billion
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $66.8 Million - $79.2 Million
-261,425 Reduced 4.55%
5,486,084 $1.49 Billion
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $179 Million - $235 Million
-795,089 Reduced 12.15%
5,747,509 $1.67 Billion
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $55.5 Million - $68.8 Million
277,804 Added 4.43%
6,542,598 $1.56 Billion
Q4 2019

Feb 18, 2020

BUY
$166.71 - $223.91 $540 Million - $726 Million
3,241,404 Added 107.21%
6,264,794 $1.37 Billion
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $20,446 - $23,012
123 Added 0.0%
3,023,390 $512 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $11 Million - $12.7 Million
-66,904 Reduced 2.17%
3,023,267 $554 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $64.3 Million - $76.4 Million
392,648 Added 14.56%
3,090,171 $568 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $26.5 Million - $33.5 Million
-174,400 Reduced 6.07%
2,697,523 $447 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $482 Million - $554 Million
2,871,923 New
2,871,923 $554 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.